Can increasing the dose of bupropion (Wellbutrin) to 450 mg cause dizziness?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 2, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, increasing bupropion to 450 mg can cause dizziness

Dizziness is a well-documented side effect of bupropion at the 450 mg dose, occurring in approximately 4-32% of patients when used in combination formulations, and is specifically listed in the FDA prescribing information as a common adverse effect. 1, 2

Understanding the Risk

The 450 mg dose represents the maximum recommended daily dose for bupropion, and adverse effects—including dizziness—are dose-related 3, 2. When you escalate from lower doses to 450 mg, you're entering the upper threshold where side effects become more frequent.

Key Evidence from FDA Labeling

The FDA drug label for Wellbutrin explicitly notes that:

  • The maximum dose should not exceed 450 mg once daily 2
  • Dose escalation should be gradual to minimize adverse events 2
  • Common side effects include dizziness, with occurrence rates ranging from approximately 4% to 32% depending on the formulation and combination 1, 4

Clinical Context

When bupropion is used in combination with naltrexone (as naltrexone/bupropion ER at 360 mg bupropion daily), dizziness is reported as one of the most common side effects 1, 4. While this is a slightly lower dose than 450 mg monotherapy, it demonstrates that dizziness is a consistent adverse effect at higher bupropion doses.

Important Safety Considerations

Dose-Related Risks Beyond Dizziness

At 450 mg, you're also at increased risk for:

  • Seizures: The seizure risk increases almost tenfold between 450-600 mg/day, with an incidence of approximately 0.4% at 300-450 mg/day 5, 2
  • Hypertension: Blood pressure elevation is more common at higher doses 2
  • Neuropsychiatric effects: Agitation, anxiety, and mood changes 2

When to Avoid 450 mg

Do not use 450 mg if the patient has:

  • Seizure disorder or conditions lowering seizure threshold 2
  • Bulimia or anorexia nervosa (seizure risk) 5, 2
  • Uncontrolled hypertension 1, 2
  • Concurrent use of other bupropion products 2

Practical Management

Titration Strategy

  • Start at 150 mg once daily for days 1-3 3, 6
  • Increase to 150 mg twice daily on day 4 if tolerated 3, 6
  • Maximum 300 mg per day is the standard maintenance dose 3, 6
  • Only escalate to 450 mg if clinically necessary and after assessing tolerance 2

Monitoring at 450 mg

  • Blood pressure at initiation and regularly during treatment 1, 2
  • Assess for dizziness, particularly in the first 1-2 weeks after dose increase
  • Watch for signs of seizure risk (tremor, agitation) 2
  • Monitor for neuropsychiatric symptoms 2

If Dizziness Occurs

The evidence from case reports shows that adverse effects from higher bupropion doses typically resolve with dose reduction or discontinuation 7, 8. If dizziness is problematic:

  • Consider reducing to 300 mg daily (the standard maximum for most indications)
  • Ensure adequate hydration
  • Rule out other contributing factors (orthostatic hypotension, drug interactions)
  • If dizziness persists despite dose reduction, discontinue the medication

Bottom Line

Dizziness at 450 mg bupropion is common and expected. The 450 mg dose should only be used when lower doses have proven inadequate, and patients must be counseled about this and other dose-related adverse effects. Gradual titration and close monitoring are essential at this maximum dose threshold.

References

Guideline

american association of clinical endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity/adiposity-based chronic disease - 2025 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2025

Guideline

attention-deficit/hyperactivity disorder in pregnancy and the postpartum period.

American Journal of Obstetrics and Gynecology, 2024

Guideline

american association of clinical endocrinologists and american college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2016

Guideline

smoking cessation, version 1.2016, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.